Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. results from a prospective study

Gut

Volumn 65, Issue 5, 2016, Pages 861-869

  Villa, Erica ^a   Critelli, Rosina ^a   Lei, Barbara ^a   Marzocchi, Guido ^b   Cammà, Calogero ^c   Giannelli, Gianluigi ^d   Pontisso, Patrizia ^e   Cabibbo, Giuseppe ^c   Enea, Marco ^c   Colopi, Stefano ^b   Caporali, Cristian ^b   Pollicino, Teresa ^f   Milosa, Fabiola ^a   Karampatou, Aimilia ^a   Todesca, Paola ^a   Bertolini, Elena ^a   Maccio, Livia ^b   Martinez Chantar, Maria Luz ^g   Turola, Elena ^a   Dal Buono, Mariagrazia ^a   De Maria, Nicola ^a   Ballestri, Stefano ^h   Schepis, Filippo ^a   Loria, Paola ^h   Gerunda, Giorgio Enrico ^b   Losi, Luisa ^b   Cillo, Umberto ^e   more..

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b ASL Modena Centro   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

^g CIC BIOGUNE   (Spain)

^h Nuovo Ospedale S Agostino   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; NUCLEAR RECEPTOR NUR77;

ADULT; AGED; ANGPT2 GENE; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DLL4 GENE; ESM1 GENE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NETO2 GENE; NR4A1 GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TRANSCRIPTOMICS; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VASCULARIZATION; DISEASE COURSE; GENETICS; LIVER TUMOR; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TIME FACTOR; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR BURDEN;

EID: 84963859125     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308483     Document Type: Article

References (38)

1. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
2. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
3. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707-16.
4. Cammà C, Di Marco V, Cabibbo G, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008;28:62-75.
5. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-16.
6. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
7. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76.
8. Kim SM, Leem SH, Chu IS, et al. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 2012;55:1443-52.
9. Woo HG, Park ES, Cheon JH, et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 2008;14:2056-64.
10. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-9.
11. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nature medicine 2003;9:416-23.
12. Villa E, Dugani A, Fantoni E, et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996;56:3883-5.
13. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000;32:233-8.
14. Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol 2014;21:1287-95.
15. Singal AG, Waljee AK, Patel N, et al. Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 2013;11:1101-8.
16. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995;22:983-93.
17. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer 1961;14:1272-94.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PC and the 2-CT method. Methods 2001;25:402-8.
19. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828-37.
20. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
21. Efron B. How biased is the apparent error rate of a prediction rule? J Am Stat Assoc 1986;81:461-70.
22. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004;103:4150-6.
23. Moon WS, Rhyu KH, Kang MJ, et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003;16:552-7.
24. Tanaka S, Mori M, Sakamoto Y, et al. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341-5.
25. Sugimachi K, Tanaka S, Taguchi K, et al. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol 2003;5:854-60.
26. Peng L, Sun J, Wang WD, et al. Biological effect of ectopic expression of angiopoietin-1 and-2 in hepatocellular carcinoma cell line. Hepatobiliary Pancreat Dis Int 2003;2:94-7.
27. Mazzieri R, Pucci F, Moi D, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011;19:512-26.
28. Lewis CE, Ferrara N. Multiple effects of angiopoietin-2 blockade on tumors. Cancer Cell 2011;19:431-3.
29. Indraccolo S, Minuzzo S, Masiero M, et al. Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res 2009;69:1314-23.
30. Ziyad S, Iruela-Arispe ML. Molecular mechanisms of tumor angiogenesis. Genes Cancer 2011;2:1085-96.
31. Skuli N, Majmundar AJ, Krock BL, et al. Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes. J Clin Invest 2012;122:1427-43.
32. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25-37.
33. Almog N, Ma L, Raychowdhury R, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009;69:836-44.
34. Vacca M, Murzilli S, Salvatore L, et al. Neuron-derived orphan receptor 1 promotes proliferation of quiescent hepatocytes. Gastroenterology 2013;144:1518-29.
35. Akeson A, Herman A, Wiginton D, et al. Endothelial cell activation in a VEGF-A gradient: relevance to cell fate decisions. Microvasc Res 2010;80:65-74.
36. Calicchio ML, Collins T, Kozakewich HP. Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. Am J Pathol 2009;174:1638-49.
37. Hanouneh IA, Macaron C, Lopez R, et al. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Transplant Proc 2011;43:3813-18.
38. Giannelli G, Rani B, Dituri F, et al. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut 2014;63:1668-76.